Cullinan Oncology to Present at H.C. Wainwright Global Investment Conference
Cullinan Oncology (NASDAQ: CGEM) announced that CFO Jeff Trigilio will present at the H.C. Wainwright Global Investment Conference from May 23-25, 2022, in Miami and online. The presentation will be available on-demand starting May 24 at 7:00 a.m. ET on the company’s investor relations website.
Cullinan focuses on developing targeted therapies for cancer, leveraging unique partnerships and a diverse pipeline aimed at enhancing patient care.
- None.
- None.
CAMBRIDGE, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for patients with cancer, today announced that its Chief Financial Officer, Jeff Trigilio, will present at the H.C. Wainwright Global Investment Conference, being held May 23-25 in Miami, FL and virtually.
A webcast of Mr. Trigilio’s presentation will be available on-demand beginning at 7:00 a.m. Eastern Time on Tuesday, May 24, 2022 under the Events section of the Company’s investor relations website at https://investors.cullinanoncology.com/news-events/events.
About Cullinan Oncology
Cullinan Oncology, Inc. (NASDAQ: CGEM) is a biopharmaceutical company dedicated to creating new standards of care for patients with cancer. We innovate without borders to find the most promising clinic-ready cancer therapies, whether from our own discovery efforts or through exceptional engagement with our academic and industry partners. Anchored in a deep understanding of immuno-oncology and translational cancer medicine, we leverage our scientific excellence in small molecules and biologics to create differentiated ideas, identify unique targets, and select the optimal modality to develop transformative therapeutics across cancer indications. Powered by our novel research model, we push conventional boundaries from candidate selection to cancer therapeutic, applying rigorous early experimentation to fast-track only the most promising assets to the clinic and ultimately commercialization. As a result, our diversified pipeline is strategically built with assets that activate the immune system or inhibit key oncogenic drivers across a wide range of modalities, each with the potential to be the best or first in their class.
Our people possess deep scientific expertise, seek innovation openly, and exercise creativity and urgency to deliver on our promise to bring new therapeutic solutions to patients with cancer. Learn more about our Company at www.cullinanoncology.com, and follow us on LinkedIn and Twitter.
Contacts:
Investor Relations
Chad Messer
+1 203.464.8900
cmesser@cullinanoncology.com
Media
Rose Weldon
+1 215.801.7644
rweldon@cullinanoncology.com
FAQ
What is the upcoming event for Cullinan Oncology in May 2022?
When will the presentation by Jeff Trigilio be available for viewing?
Where can I find the webcast of Cullinan Oncology's presentation?
What is the focus of Cullinan Oncology as a biopharmaceutical company?
What is the stock symbol for Cullinan Oncology?
